Scoop: In­Car­da ter­mi­nates its PhI­II tri­al for ar­rhyth­mia drug that was cen­tral to plans for an IPO

In­Car­da Ther­a­peu­tics has ter­mi­nat­ed its Phase III tri­al for an in­haled ver­sion of an ir­reg­u­lar heart­beat drug be­cause of “lim­it­ed ef­fi­ca­cy,” ac­cord­ing to a US clin­i­cal tri­als data­base, po­ten­tial­ly spelling an end to the Cal­i­for­nia biotech’s sole clin­i­cal-stage as­set.

While In­Car­da hasn’t com­ment­ed pub­licly on the end of the tri­al, an up­date on the pro­gram was post­ed June 9 on clin­i­cal­tri­als.gov. The study, known as RE­STORE-1, was stopped be­cause of “lim­it­ed ef­fi­ca­cy up­on blind­ed re­view,” ac­cord­ing to the site.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER